Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

Incyte

Surging Trulicity takes sting out of Lilly's arthritis setback

Surging Trulicity takes sting out of Lilly's arthritis setback Incyte-partnered baricitinib, which had previously been forecast to make $2bn or more in peak sales.

FDA turns down Lilly and Incyte JAK inhibitor after delay

FDA turns down Lilly and Incyte JAK inhibitor after delay Lilly/Incyte drug's safety profile and dosing data, and needs more clinical information. ... Xeljanz is approaching blockbuster status - bringing in $927m last year - but has failed to meet initial sales projections and Lilly and Incyte had hoped

Apexigen and BMS team up for lung cancer immunotherapy trial

Apexigen and BMS team up for lung cancer immunotherapy trial BMS already has a swathe of such alliances in place, most recently signing a wide-ranging alliance with Incyte to combine Opdivo with its IDO1 inhibitor epacadostat in clinical trials, including

BMS closes in on colorectal cancer indication for Opdivo

BMS closes in on colorectal cancer indication for Opdivo For good measure, BMS has also signed an expanded agreement for combination studies of Opdivo with Incyte's IDO1 inhibitor epacadostat, including phase III pivotal trials in first-line NSCLC and ... Rival Merck &Co – which sells PD-1 inhibitor Keytruda

Deal Watch February 2017

Deal Watch February 2017 In addition, Incyte is purchasing 10m shares of Agenus common stock at $6 per share. ... Acquisition - products. 88.3. Agenus/ Incyte. GITR and OX40 antibody programmes converted from co-funded dev/profit-sharing to royalty-bearing arrangement (phase I).

[ Previous 5 results ] 6 7 8 9 10 11 12 13 14 15 [ Next 5 results ]

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
90TEN

90TEN is a global healthcare communications consultancy with a mission to make people healthier and happier through life-changing education and...

Latest intelligence

The immunotherapy knowledge gap: keeping the patient at the heart of cancer treatment
Advances in cancer treatment are frequent, but how much do we actually understand about these new treatments?...
Value is in the eye of the customer. Co-creation is a bridge to value.
We conducted 16 hours of qualitative interviews with HCPs and Senior Pharma industry leaders in the UK, supported with in-depth industry scanning. Our interviews reveal important insights about the tensions...
Partnering with Patients and Caregivers in Clinical Research
...